BioSpace News Archive

Bluestar Genomics, Inc. announced the results from multiple studies highlighting the expansion of the company’s technology platform into ovarian cancer detection and tumor tissue analysis.

Agomab Therapeutics NV (‘Agomab’) today announced that Fierce Biotech has named the company as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Cellusion Inc. and Hangzhou Celregen Therapeutics Ltd., a member of Shanghai Fosun Pharmaceutical Co., Ltd.,and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital, announced an exclusive license agreement in the Greater China region for Celregen to develop, manufacture and commercialize CLS001.

Sensorion announces that the European Medicines Agency Committee for Orphan Medicinal Products has adopted a positive opinion on Sensorion’s application for Orphan Drug Designation for its lead therapy gene candidate, OTOF-GT, a gene therapy intended for the treatment of otoferlin gene mediated hearing loss.

RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and present a company overview during the 22 nd Annual Biotech in Europe Forum, being held September 21-22, 2022, in Basel, Switzerland.

NeoImmuneTech, Inc., a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology Congress in Paris, France, September 9-13, 2022.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce the publication of results from a clinical study undertaken in partnership with the Wilmot Cancer Institute, University of Rochester, NY, US.

Regeneron Pharmaceuticals, Inc. announced the presentation of positive data from multiple expansion cohorts of an initial Phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® in advanced melanoma.

IRLAB Therapeutics IRLAB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the last participating patient has been randomized and entered the ongoing Phase IIb study of lead candidate mesdopetam.

Keros Therapeutics, Inc. announced that it presented preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 clinical trial of KER-012 in healthy postmenopausal women at the American Society of Bone and Mineral Research 2022 Annual Meeting on Sunday, September 11, 2022.